Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Increased expression of Akt2 and activity of PI3K and cell proliferation with the ascending of tumor grade of human gliomas.

Wang G, Kang C, Pu P.

Clin Neurol Neurosurg. 2010 May;112(4):324-7. doi: 10.1016/j.clineuro.2010.01.003. Epub 2010 Feb 8.

PMID:
20116920
2.

Interaction between Ras(V12) and scribbled clones induces tumour growth and invasion.

Wu M, Pastor-Pareja JC, Xu T.

Nature. 2010 Jan 28;463(7280):545-8. doi: 10.1038/nature08702. Epub 2010 Jan 13. Erratum in: Nature. 2017 Mar 16;543(7645):452.

3.

Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-kappaB signaling pathways.

Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N, Sarkar FH.

J Cell Biochem. 2010 Mar 1;109(4):726-36. doi: 10.1002/jcb.22451. Erratum in: J Cell Biochem. 2016 Aug;117(8):1960.

PMID:
20052673
4.

Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade.

Ma J, Meng Y, Kwiatkowski DJ, Chen X, Peng H, Sun Q, Zha X, Wang F, Wang Y, Jing Y, Zhang S, Chen R, Wang L, Wu E, Cai G, Malinowska-Kolodziej I, Liao Q, Liu Y, Zhao Y, Sun Q, Xu K, Dai J, Han J, Wu L, Zhao RC, Shen H, Zhang H.

J Clin Invest. 2010 Jan;120(1):103-14. doi: 10.1172/JCI37964. Epub 2009 Dec 28.

5.

Time trends in brain tumor incidence rates in Denmark, Finland, Norway, and Sweden, 1974-2003.

Deltour I, Johansen C, Auvinen A, Feychting M, Klaeboe L, Schüz J.

J Natl Cancer Inst. 2009 Dec 16;101(24):1721-4. doi: 10.1093/jnci/djp415.

PMID:
19959779
6.

mTOR and cancer: many loops in one pathway.

Efeyan A, Sabatini DM.

Curr Opin Cell Biol. 2010 Apr;22(2):169-76. doi: 10.1016/j.ceb.2009.10.007. Epub 2009 Nov 27.

7.

Chromosome 7 and 19 trisomy in cultured human neural progenitor cells.

Sareen D, McMillan E, Ebert AD, Shelley BC, Johnson JA, Meisner LF, Svendsen CN.

PLoS One. 2009 Oct 29;4(10):e7630. doi: 10.1371/journal.pone.0007630.

8.

Brain cancer propagating cells: biology, genetics and targeted therapies.

Hadjipanayis CG, Van Meir EG.

Trends Mol Med. 2009 Nov;15(11):519-30. doi: 10.1016/j.molmed.2009.09.003. Epub 2009 Nov 2. Review.

9.

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.

Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S.

Nature. 2009 Oct 8;461(7265):809-13. doi: 10.1038/nature08489.

PMID:
19812674
10.

Heterogeneity in cancer: cancer stem cells versus clonal evolution.

Shackleton M, Quintana E, Fearon ER, Morrison SJ.

Cell. 2009 Sep 4;138(5):822-9. doi: 10.1016/j.cell.2009.08.017.

11.

Rapamycin inhibits mTORC1, but not completely.

Thoreen CC, Sabatini DM.

Autophagy. 2009 Jul;5(5):725-6. Epub 2009 Jul 22.

PMID:
19395872
12.

Neurosphere formation is an independent predictor of clinical outcome in malignant glioma.

Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI.

Stem Cells. 2009 Apr;27(4):980-7. doi: 10.1002/stem.15.

13.

Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways.

Li Z, Wang H, Eyler CE, Hjelmeland AB, Rich JN.

J Biol Chem. 2009 Jun 19;284(25):16705-9. doi: 10.1074/jbc.R900013200. Epub 2009 Mar 13. Review.

14.

A hierarchical cascade activated by non-canonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced death in mammalian cells.

Perumalsamy LR, Nagala M, Banerjee P, Sarin A.

Cell Death Differ. 2009 Jun;16(6):879-89. doi: 10.1038/cdd.2009.20. Epub 2009 Mar 6.

15.

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS.

J Biol Chem. 2009 Mar 20;284(12):8023-32. doi: 10.1074/jbc.M900301200. Epub 2009 Jan 15.

16.

PI3K inhibitors for cancer treatment: where do we stand?

Maira SM, Stauffer F, Schnell C, García-Echeverría C.

Biochem Soc Trans. 2009 Feb;37(Pt 1):265-72. doi: 10.1042/BST0370265. Review.

PMID:
19143644
17.

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors.

Carracedo A, Baselga J, Pandolfi PP.

Cell Cycle. 2008 Dec 15;7(24):3805-9. Epub 2008 Dec 22. Review.

18.

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, De Maria R.

Clin Cancer Res. 2008 Dec 15;14(24):8205-12. doi: 10.1158/1078-0432.CCR-08-0644.

19.

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, Downing JR.

Science. 2008 Nov 28;322(5906):1377-80. doi: 10.1126/science.1164266.

20.

Notch, neural stem cells, and brain tumors.

Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N.

Cold Spring Harb Symp Quant Biol. 2008;73:367-75. doi: 10.1101/sqb.2008.73.013. Epub 2008 Nov 6. Review.

Supplemental Content

Support Center